HC Wainwright Has Bullish Estimate for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at HC Wainwright increased their FY2025 earnings per share estimates for BioCryst Pharmaceuticals in a research note issued on Monday, December 15th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of $0.11 for the year, up from their previous estimate of $0.09. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2027 earnings at $0.31 EPS.

BCRX has been the topic of a number of other research reports. JMP Securities raised their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 15th. Cantor Fitzgerald upped their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Citizens Jmp reduced their price target on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, November 5th. Zacks Research cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, TD Cowen started coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price objective for the company. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.50.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $7.59 on Tuesday. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31. The stock has a 50 day simple moving average of $7.16 and a 200-day simple moving average of $8.20. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -151.80 and a beta of 0.91.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The firm had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. During the same quarter in the prior year, the business posted ($0.07) EPS. The firm’s quarterly revenue was up 36.1% compared to the same quarter last year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 91,004 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $7.10, for a total transaction of $646,128.40. Following the completion of the transaction, the insider directly owned 416,152 shares in the company, valued at $2,954,679.20. This trade represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 161,680 shares of company stock worth $1,164,401. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Nuveen LLC acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter worth approximately $10,677,000. Russell Investments Group Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 269.5% in the first quarter. Russell Investments Group Ltd. now owns 103,329 shares of the biotechnology company’s stock valued at $775,000 after acquiring an additional 75,363 shares in the last quarter. Algert Global LLC boosted its holdings in BioCryst Pharmaceuticals by 32.4% in the first quarter. Algert Global LLC now owns 960,057 shares of the biotechnology company’s stock valued at $7,200,000 after purchasing an additional 234,752 shares during the period. Wellington Management Group LLP grew its stake in BioCryst Pharmaceuticals by 2.6% during the 1st quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock worth $685,000 after purchasing an additional 2,291 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at about $304,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.